Eli Lilly Deal Activity — 38 Deals Analyzed (2025–2026)

Eli Lilly closed 38 deals between February 15, 2025, and July 7, 2026 — an aggressive cadence of roughly one deal every 12 days. The therapeutic concentration tells a clear story: neurology and oncology dominate, with mega-deals and rare disease rounding out a portfolio that signals Lilly is not just maintaining its pipeline — it's rebuilding entire therapeutic franchises at scale. The June 2026 acquisition of cleminorexant for $6.3 billion and the Centessa Pharmaceuticals transaction days later make the intent unambiguous. Lilly is deploying capital at a pace and magnitude that few buyers in biopharma can match right now.

Eli Lilly's Deal Portfolio

The therapeutic area distribution across these 38 deals spans ten categories — mega-deals, oncology, neurology, rare disease, gastroenterology, infectious disease, cardiovascular, metabolic, ophthalmology, and other — but the weight is disproportionately concentrated. Neurology accounts for multiple high-value transactions, including two Alzheimer's-focused deals announced within 24 hours of each other (June 8–9, 2026) with a combined TDV of $2 billion. Oncology shows up repeatedly at the discovery and platform level, not late-stage asset grabs. Rare disease and gastroenterology are emerging flanks, not afterthoughts — the RNA exon-editing deal at $1.9 billion TDV and the Phase 2 GLP-2 agonist indicate Lilly is placing deliberate bets outside its core.

This is not diversification for its own sake. It's a company systematically building depth in neurology, breadth in oncology, and optionality in adjacent areas where its metabolic franchise creates strategic leverage.

Deal Type Preferences

Lilly's preferred deal structures — acquisitions, collaborations, and licenses — reveal a buyer that modulates risk exposure deal by deal. The Centessa acquisition and the $6.3 billion cleminorexant deal represent outright ownership plays where Lilly eliminated optionality in favor of control. The AI-driven drug discovery collaboration ($2.75 billion TDV) and the Ajax oncology collaboration ($2.3 billion TDV) are structured to retain flexibility, spreading capital across milestones while locking in access to platforms and multi-target programs.

The average upfront ratio across this 38-deal portfolio sits at 48.9% of total deal value. That number deserves scrutiny. A sub-50% upfront ratio is, in aggregate, buyer-friendly — Lilly is keeping roughly half of total consideration contingent on milestones. But the cleminorexant deal distorts the picture: at $6.3 billion upfront out of $6.3 billion TDV, that's a 100% upfront ratio, meaning Lilly paid full price with no milestone structure. Strip that deal out, and the remaining portfolio's upfront ratio drops meaningfully, suggesting Lilly's default posture on collaborations and licenses is to push milestone-heavy structures that protect downside.

For sellers, the takeaway is nuanced. Lilly will pay full freight — even billions upfront — for assets it considers must-haves. For everything else, expect structured deals where 50–70% of total value sits behind development and commercial milestones. Use the Deal Calculator to benchmark where your asset's upfront ratio should land relative to Lilly's historical pattern.

Strategic Pattern

Three strategic threads connect the dots across Lilly's 38 deals:

• Neurology franchise rebuild around Alzheimer's. The cleminorexant acquisition ($6.3B), the AlzeCure preclinical candidate ($1B TDV), and the gamma-secretase modulator ($1B TDV) represent a coordinated effort to build a multi-mechanism Alzheimer's portfolio. Lilly is not betting on one target — it's assembling a portfolio that hedges across orexin antagonism, gamma-secretase modulation, and earlier-stage mechanisms. This is a company that lived through the solanezumab failures and learned. The combined neurology commitment in visible deals alone exceeds $8 billion in TDV. Lilly is making neurology a second pillar alongside metabolic disease.
• Oncology at the platform level. The multitarget oncology programs ($1.9B TDV, discovery stage) and the Ajax collaboration ($2.3B TDV) are both structured around platforms, not single assets. Lilly is buying optionality across multiple targets rather than paying up for late-stage oncology assets in competitive auctions. This is a deliberate counter-strategy to the Pfizer/Seagen or AbbVie/ImmunoGen model of paying premium multiples for commercial-stage oncology. Lilly wants to own the discovery funnel. Compare these to mega-deal benchmarks to see how Lilly's platform bets compare to single-asset acquisitions.
• AI and next-generation modalities as infrastructure plays. The $2.75 billion AI-driven drug discovery collaboration and the $1.9 billion RNA exon-editing deal are not traditional pharma licensing. These are bets on enabling technologies — AI for multi-target identification and RNA editing for genetic diseases. Lilly is investing in the tools, not just the outputs. That signals a company thinking about 2030+ pipeline generation, not just filling near-term gaps.

The Centessa acquisition (July 7, 2026) is the capstone. Centessa's multi-asset, multi-program model fits Lilly's pattern of buying platforms rather than individual programs. It's consistent with everything else in this dataset: Lilly prefers optionality, breadth, and control over single-asset risk.

What This Means If You're Pitching to Eli Lilly

If you're a biotech looking to partner with Lilly, here's what the data tells you about how to position:

• Neurology and oncology are the highest-probability therapeutic areas. These two TAs account for the largest concentration of deal value. If your asset is in Alzheimer's disease, neurodegeneration, or multi-target oncology, you are in Lilly's strike zone. Rare disease — particularly genetic approaches like RNA editing — is an emerging area of interest but with fewer data points.
• Lead with platform, not single-asset stories. Lilly's deal pattern favors multi-target collaborations and platform acquisitions. If you have a single clinical-stage asset, you can still get a deal done, but you will likely face a milestone-heavy structure. If you can position your company as a platform with multiple shots on goal, you increase the probability of a mega-deal structure and potentially better upfront economics.
• Propose a 45–55% upfront ratio as your baseline. Lilly's 48.9% average upfront ratio is the anchor. Come in asking for 60%+ upfront and be prepared to justify it with clinical data, competitive dynamics, or scarcity value. If you're preclinical or discovery-stage, expect Lilly to push you toward 30–40% upfront with heavy milestone loading. The exception: if your asset is a must-have in a competitive process, Lilly has demonstrated willingness to go to 100% upfront (see cleminorexant).
• Expect Lilly to move fast on competitive assets. The June 2026 cadence — seven significant deals in five weeks — shows a BD team operating at sprint pace. If you create competitive tension with other large-cap buyers, Lilly will accelerate. If you're running a single-track negotiation, expect a more measured timeline and tighter terms.
• Structure your ask around collaboration or license, not M&A, unless you're Series C+ with multiple clinical programs. Lilly's acquisitions (Centessa, cleminorexant) targeted either company-level platform plays or late-stage high-conviction assets. For earlier-stage biotechs, the collaboration and license path is more realistic. Structure your term sheet accordingly.

Run your asset through Ambrosia's partner matching engine to see how it scores against Lilly's deal profile — and against 850+ other potential buyers. The model incorporates therapeutic area fit, stage preference, deal structure patterns, and historical upfront ratios to rank your best-fit partners.